IQVIA Holdings Inc. (IQV)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 11 | 14 | 14 | 15 | 15 | 16 | 17 | 17 |
| Operating profit | $bn | 2 | 2 | ||||||
| Net profit | $bn | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| EPS reported | $ | 7.84 | 8.06 | ||||||
| Operating cashflow per share | $ | 15.44 | 16.86 | ||||||
| Capex per share | $ | 3.51 | 1.23 | ||||||
| FCF per share | $ | 11.93 | 15.63 | ||||||
| Free cash flow | $bn | 2 | 3 | ||||||
| Net debt | $bn | 14 | 14 | ||||||
| Book value equity | $bn | 7 | 6 | ||||||
| Book value per share | $ | 37.48 | 36.60 | ||||||
| Number of shares | m | 173.5 | 168.6 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 28.75 | 33.54 | ||||||
| P/B LTM | x | 5.96 | 6.28 | ||||||
| P/S LTM | x | 2.38 | 2.28 | ||||||
| P/FCF LTM | x | 18.89 | 14.83 | ||||||
| EV/EBITDA LTM | x | 15.28 | 15.01 | ||||||
| EV/Sales LTM | x | 3.25 | 3.14 | ||||||
| Earnings Yield LTM | % | +3.48% | +2.98% | ||||||
| FCF Yield | % | +5.29% | +6.74% | ||||||
| Quality | |||||||||
| ROE | % | +20.91% | +21.95% | ||||||
| ROIC | % | +8.23% | +8.32% | ||||||
| Operating margin | % | +14.02% | +13.57% | ||||||
| Gross margin | % | +26.28% | +26.23% | ||||||
| FCF/Sales | % | +12.58% | +15.39% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +4.67% | +7.61% | ||||||
| Sales Growth YoY | % | +5.87% | +10.24% | ||||||
| Net Income Growth YoY | % | -0.95% | +0.15% | ||||||
| FCF Growth | % | -2.98% | +23.60% | ||||||
| Operating Profit Growth | % | +3.86% | +4.68% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.13 | 0.16 | ||||||
| Net Debt/EBITDA | x | 4.10 | 4.06 | ||||||
| EBIT/Net interest | x | 3.14 | 2.99 | ||||||
| Net debt/market cap | % | +41.16% | +41.07% | ||||||
| Net debt/Equity | x | 2.12 | 2.26 | ||||||
| Gross debt/equity | x | 2.49 | 2.63 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free